Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al (2018) LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Continued daily use maintains the collagen density achieved, prevents further degradation, and continues the gene-level anti-aging effects that slow the rate of future aging
Running Retatrutide solo first is a perfectly sound starting point, with Cagrilintide added later if appetite control needs reinforcing
Related Reading Can You Get Your Glp 1 Tested Maximus Glp 1 Found Glp 1 Orderly Meds Glp 1 Medical and Editorial Standards Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims